iRhythm Technologies (IRTC) Expects 2025 Revenue to Exceed $740 Million, 2026 Revenue of $870 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- 2025 Revenue Outlook: iRhythm anticipates 2025 revenue will exceed the high end of the $740 million guidance, driven by record unit volume in Q4, indicating strong growth potential in the digital health sector.
- 2026 Financial Projections: The company expects revenue of approximately $870 million to $880 million in 2026, reflecting a year-over-year growth of 17% to 18%, surpassing the analyst consensus of $862.68 million, showcasing its competitive strength in the market.
- Market Expansion Strategy: iRhythm plans to deepen penetration in primary care and population health through AI-powered risk stratification partnerships while expanding into adjacent markets like obstructive sleep apnea, highlighting its diversified growth strategy.
- Stock Reaction and Analysis: Despite a 20% drop in iRhythm's stock due to the delay of Zio MCT to 2027, William Blair analysts believe the weakness is overstated and recommend investors seize the buying opportunity, maintaining an Outperform rating.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 222.00 USD with a low forecast of 205.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 148.990
Low
205.00
Averages
222.00
High
244.00
Current: 148.990
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. It designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using its Zio Systems. The Zio Monitor System is a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for over 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
Continue Reading
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
Continue Reading